Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01899742 · ClinicalTrials.gov registry record · Phase 3
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 497
- Enrollment target
NCT01899742 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 497 participants.
The verdict
NCT01899742, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 497 participants
- Enrollment target
Study Summary
The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and continue to have symptoms while on tiotropium.
Interventions
- DRUG Tiotropium 18 mcg
- DRUG Umeclidinium/Vilanterol 62.5/25 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2014-09-15 |
| Est. Completion | 2015-07-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01899742
The ClinicalTrials.gov registry entry for NCT01899742 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 497 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium 18 mcg is the first listed.
NCT01899742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01899742 about?
NCT01899742 is a clinical study titled "The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium". The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and continue to have symptoms while on tiotropium.
What is the current status of trial NCT01899742?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 497 participants. The study started on 2014-09-15. Estimated completion is 2015-07-22.
What interventions are being tested in trial NCT01899742?
The interventions under investigation include: Tiotropium 18 mcg (DRUG), Umeclidinium/Vilanterol 62.5/25 mcg (DRUG).
Who is sponsoring clinical trial NCT01899742?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.